drug · antibody
mavrilimumab
Phase 2updated 3mo agoby MedImmune Ltd🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Phase 2 3 (across all indications), with 2 investigational indications.
indications
indications
Rheumatoid Arthritis
targets
Granulocyte-macrophage colony-stimulating factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying mavrilimumab
- phase3Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
- phase2Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
- phase2KPL-301 for Subjects With Giant Cell Arteritis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that